A028 The Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS): Baseline Characteristics of Patients With First-time ACS

Abstract

Each year, approximately 5000 New Zealanders are admitted to hospital with a first-time acute coronary syndrome (ACS). The aim of the Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS) is to examine the relationship of clinical, genomic and cardiometabolic markers in relation to presentation and outcomes post-ACS. MENZACS is a prospective, longitudinal cohort study embedded within the All New Zealand Acute Coronary Syndrome Quality Improvement (ANZACS-QI) programme in 6 hospitals. Patients with first-time ACS were enrolled and study-specific research data collected alongside the ANZACS-QI registry. Research blood samples were stored for future genetic/biomarker assays. We report here the baseline characteristics of the MENZACS cohort and compare to the ANZACS-QI registry (first-time ACS). Between 2015-2019, 2026 patients were enrolled, mean age 61yrs, 21% were female. Ethnicity and CV risk factor distribution was similar to ANZACS-QI: 13% Māori, 5% Pacific, 5% Indian and 74% NZ European. CV risk factors included 56% ex-/current smoker, 42% hypertension, 18% diabetes. 60% of the patients were aged < 65 years. ACS subtype for MENZACS vs ANZACS-QI: STEMI 40% vs 31%, NSTEMI 52% vs 59%. 99% had coronary angiography and 90% had revascularisation; there were high rates of secondary prevention medications (table).Tabled 1Discharge MedicationAspirin1927 (98%)Dual antiplatelet therapy1611 (82%)Statin1922 (97%)Beta-blocker1652 (84%)ACEi/ARB1550 (79%) Open table in a new tab MENZACS represents a cohort with optimal contemporary management and will be a significant epidemiological bioresource for the study of environmental and genetic factors contributing to ACS in New Zealand's multi-ethnic environment. The study will utilise clinical, nutritional, lifestyle, genomic and biomarker analyses to explore aetiological factors and develop risk prediction models for outcome.